ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Manish Shah on the METGastric Study

Manish A. Shah, MD
Published: Thursday, Jun 04, 2015



Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the METGastric study.

The METGastric study examined onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction. Previous data demonstrated that onartuzumab has activity against the MET receptor. Onartuzumab is considered a novel agent, Shah says, because it is a single chain of the IgG molecule that inhibits the MET pathway and the HGF binding.

Patients were randomized to receive either mFOLFOX6 or mFOLFOX6 combined with onartuzumab. The study ended prematurely due to lack of efficacy, Shah says.



Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the METGastric study.

The METGastric study examined onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction. Previous data demonstrated that onartuzumab has activity against the MET receptor. Onartuzumab is considered a novel agent, Shah says, because it is a single chain of the IgG molecule that inhibits the MET pathway and the HGF binding.

Patients were randomized to receive either mFOLFOX6 or mFOLFOX6 combined with onartuzumab. The study ended prematurely due to lack of efficacy, Shah says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x